Zhang C. Connecting asciminib tolerability to long-term treatment persistence. Comment on: "Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia". Haematologica [Internet]. 2026Jul.23 [cited 2026Nov.5];. Available from: https://haematologica.org/article/view/14321